Omeros (OMER) announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in patients with transplant-associated thrombotic microangiopathy treated with narsoplimab. The data is from a global expanded access program and reports outcomes in patients treated with narsoplimab as a first-line therapy and in those who failed prior treatments. A biologics license application for narsoplimab in TA-TMA is currently under review by the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Omeros Corporation’s Positive Earnings Call Highlights Progress
- Largest borrow rate increases among liquid names
- Omeros’s Strategic Advancements with Narsoplimab: A Buy Rating Amidst Promising FDA and EMA Reviews
- Omeros Corporation Reports Q2 2025 Financial Results
- Closing Bell Movers: UnitedHealth jumps 10% as Berkshire, Appaloosa buy weakness